The Probiotic That Ignores Your Antibiotics Was Never a Bacterium

The Oasis Health Journal · Submitted July 11, 2026 · 8:20 AM ET

Here is a scheduling problem nobody warns you about. Your doctor hands you antibiotics. The internet hands you probiotics. Antibiotics kill bacteria. Most probiotics are bacteria. So you are hiring a cleaning crew and setting off a bug bomb in the same room, then wondering why the floor is still sticky.

Saccharomyces boulardii is the one probiotic that ducks the whole fight. Not because it is tougher than the others. Because it is not a bacterium at all. It is a yeast. Antibacterial antibiotics walk right past it, the way a mousetrap ignores a pigeon.

A yeast with a passport

S. boulardii is a tropical cousin of brewer's yeast (Saccharomyces cerevisiae). The story goes that a French microbiologist named Henri Boulard found it in the 1920s while watching people in Southeast Asia chew lychee and mangosteen skins to settle their stomachs during a cholera outbreak. He bottled the yeast. It still carries his name and a strain code, CNCM I-745, which is science's way of saying 'this exact one, not the stuff floating in your beer.'

Because it is a fungus, the antibiotic you take for a sinus infection cannot touch it. That is the entire trick, and it is a good one. (Antifungal drugs are a different story. Those do kill it. Yeast is not invincible, it just found a specific loophole and moved in.)

What the trials actually say

The best-studied job for S. boulardii is preventing the diarrhea that antibiotics themselves cause. A 2015 systematic review in Alimentary Pharmacology and Therapeutics pooled 21 randomized trials and roughly 4,780 people. Antibiotic-associated diarrhea showed up in 18.7 percent of the control group and 8.5 percent of the S. boulardii group. That is a relative risk of 0.47, or about one case prevented for every ten people who take it alongside their antibiotics. Not a miracle. A solid, boring, repeatable result, which is the best kind.

Then there is the sick-toddler department. A 2025 meta-analysis led by Lynne McFarland pulled together 10 randomized trials and 1,125 children with acute gastroenteritis. Kids on S. boulardii CNCM I-745 had diarrhea for about 1.6 days less, were noticeably more likely to be fully cured (relative risk 1.47), and even showed lower levels of two inflammation markers, TNF-alpha and IL-8. Reviews of children outside China have leaned the same direction for years.

Now the honest part, because we do not run infomercials here. Every one of those 2025 pediatric trials came from China, all were open-label (nobody was blinded to who got what), and the authors themselves flagged publication bias and a lot of variation between studies. Translation: the direction is encouraging and consistent, but treat the exact number of days as a friendly estimate, not a stopwatch reading.

It does not move in, it just visits

Here is the part people get wrong. S. boulardii does not colonize your gut. It does not plant a flag or start a family. Take it and it shows up in your stool within days. Stop, and it clears out in about the same window. It is a bouncer working a single shift, not a tenant on the lease.

During that shift it earns its pay. In human colon tissue, S. boulardii releases a 54-kilodalton protease, an enzyme that snips apart Clostridioides difficile toxins A and B and even chews up the docking site those toxins use to grab your gut wall. It also nudges up secretory IgA (your gut's front-desk antibody) and feeds the cells lining your intestine. For a microbe that is only passing through, it does a suspicious amount of chores.

Who should skip it

This is where the deadpan stops. S. boulardii is a live yeast, and in the wrong patient a live yeast can slip into the bloodstream. A 2021 CDC study in Emerging Infectious Diseases reviewed 46 cases of Saccharomyces fungemia in Finnish hospitals. At least 43 percent of those patients had been given the probiotic, and their odds of having used it were 14 times higher than matched controls. Almost all were seriously ill, many with a central venous catheter (do not open a sachet of live yeast next to one of those). Regulators including the European Medicines Agency now advise against it in people who are critically ill, immunocompromised, or catheterized. In the United States it is sold as a dietary supplement. In France it has been a registered medicine for decades. Same yeast, different paperwork.

For a healthy adult riding out a course of antibiotics or a bout of traveler's diarrhea, that risk is very low. But 'very low' is not 'zero,' and if you are handing anything to someone fragile, that is a conversation for their doctor, not a blog post.

The Oasis angle

A yeast is only useful if enough of it is still alive when it reaches you. Potency quietly fades as a product sits in a warehouse getting older by the month. That is why we source our Saccharomyces boulardii and the rest of our probiotics fresh per order instead of stockpiling them. It makes our shipping slower. It also means you get the count printed on the label, not the count that survived a year on a shelf. If you are rebuilding after antibiotics, people often pair it with digestive enzymes and a broader gut health routine. Slower to arrive, stronger when it does. We think that trade is worth it.

This article is for education only and is not medical advice. Talk with a qualified clinician before starting any supplement, especially if you are pregnant, immunocompromised, seriously ill, or caring for a young child.

Sources

1. Szajewska H, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Alimentary Pharmacology and Therapeutics, 2015.
2. McFarland LV, Li T. Efficacy and safety of Saccharomyces boulardii CNCM I-745 for the treatment of pediatric acute diarrhea in China: a systematic review and meta-analysis. Frontiers in Cellular and Infection Microbiology, 2025.
3. Castagliuolo I, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infection and Immunity, 1999.
4. Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Alimentary Pharmacology and Therapeutics, 2007.
5. Rannikko J, et al. Fungemia and other fungal infections associated with use of Saccharomyces boulardii probiotic supplements. Emerging Infectious Diseases (CDC), 2021.